The cardiovascular effects of ergometrine have been examined using animal models in vivo and in vitro. In rats in vivo the pressor effects of a standard dose of ergometrine were found to be dependent upon the anaesthetic used for the procedure. The pressor action of ergometrine was greater when urethane, an anaesthetic which produces both sympathetic and parasympathetic activity, was used. The in-vitro experiments, using isolated rabbit aorta and portal vein, failed to explain the phenomenon; they suggested that ergometrine has a direct action on the alpha-adrenoceptor in rabbits. No evidence was found to suggest that ergometrine inhibits noradrenaline uptake or its release from the nerve terminals.
arterial pressure was monitored using a pressure transducer connected to a Grass 79G polygraph. A record of heart rate was obtained from a rate meter triggered from the arterial pressure recording.
Drugs, dissolved in 0.2 ml saline, were administered via the jugular vein. Each dose was washed in by a further 0.2 ml of saline.
Arterial pressure responses to injections of noradrenaline bitartrate, ergometrine maleate and vasopressin were investigated. The effects of propranolol hydrochloride 200 ng and phentolamine mesylate 10 mg (in divided doses) on these responses were studied.
Rabbit aorta and portal vein.
Male and female rabbits of mixed strain were used.
The rabbits were killed by a blow on the head, and the thoracic aorta or the hepatic portal vein removed. Spirally cut strips of either aorta or portal vein were set up at 37 "C in Krebs solution gassed with 5% carbon dioxide in oxygen.
The characteristics of spiral strips of rabbit aorta have been fully described by Furchgott and Bhadrakom (1953) . The spirally cut portal vein has been described by Kelly (1971) who found that this preparation had considerably less myogenic activity than the longitudinal strip described by Hughes and Vane (1967) .
Responses of the tissues were measured isotonically using an "Ether" strain gauge connected to a Smiths RE52O potentiometric recorder.
The activity of ergometrine on these two prepare-tions was compared with noradrenaline, which acts principally on a-adrenoceptors, and tyramine, which acts by releasing noradrenaline from the nerve terminals. Cumulative concentration response relationships were obtained using a 5-min contact time on the aorta and a 2-min contact time on the portal vein.
Cumulative concentration response relationships to the three agents were also obtained on portal vein strips exposed 1X10 5 M cocaine and on portal vein from rabbits pretreated with reserpine 2 mg/kg for three days.
Interactions with noradrenaline were examined by obtaining concentration response curves to noradrenaline in the presence of various concentrations of ergometrine and vice versa.
Finally, interactions between ergometrine and the o-adrenoceptor blocking agent, phentolamine, were examined and the pA, value for phentolamine against ergometrine was obtained by the method of Arunlakshana and Schild (1959) . A pA, value is a measure of antagonist potency and is defined as the negative logarithm of the concentration of an antagonist which will reduce the response produced by a concentration of agonist 2x to that produced by a concentration x. From theoretical considerations based on the law of mass action, Arunlakshana and Schild (1959) suggested that antagonism could be considered competitive if it fulfilled certain requirements. Firstly, the antagonist should cause a parallel displacement of the log concentration effect curve of the agonist to the right. Secondly, there should be no diminution of the tnavimnTn response to the agonist. Finally when log (dose ratio -1) is plotted against the negative log concentration of antagonist a straight line should result with a slope of -1. In these circumstances pA,-pA 10 =0.95. The interaction between phentolamine and ergometrine has been examined with these requirements in mind.
Results are expressed as mean values ±SE and significance levels were calculated using the Student Mest.
RESULTS

Rat arterial pressure.
The initial mean arterial pressure in a group of 10 rats anaesthetized with urethane was 80.7 ±5.1 mm Hg and the heart rate was 264 ±15 beats/min. Corresponding values in pentobarbitone-anaesthetized rats were 122 ±4.2 mm Hg and 286 ±20 beats/min («=5).
It was possible to obtain a dose-related pressor response to both noradrenaline and vasopressin in rats anaesthetized with both agents. Maximum responses to ergometrine were considerably less than responses obtained with moderate doses of vasopressin and noradrenaline. The maximum response to ergometrine occurred with 160 ng in urethaneanaesthetized rats and 320 ng in the pentobarbitoneanaesthetized rats. In view of this mnYimnm effect of ergometrine it was not possible to obtain meaningful potency ratios between noradrenaline, vasopressin and ergometrine. Thus the effects of standard doses of the three drugs have been compared on the arterial pressure of rats treated with the two anaesthetics. The doses selected were 80 ng noradrenaline, 160 ng ergometrine and 5 mU vasopressin and the results obtained are shown in table I.
Only the effects of ergometrine were significantly different (P<0.001) on the two preparations. Ergometrine was a more potent pressor agent when the rat was anaesthetized with urethane.
No consistent changes in heart rate were seen with any of the pressor agents.
Propranolol 200 ng had no significant effect on the arterial pressure or heart rate of rats anaesthetized with pentobarbitone. However, in rats anaesthetized with urethane, heart rate was reduced by 63 ±9 beats/min and the arterial pressure increased by 26.9 ±3.1 mm Hg. Under both anaesthetics the mean arterial pressure response to noradrenaline 40 and 80 ng, ergometrine 80 and 160 ng, and vasopressin 2.5 and 5 mU were slightly enhanced.
Phentolamine 10 mg, had similar effects under both anaesthetics. In urethanized rats phentolamine produced a decrease in the mean arterial pressure of 33 ± 3.9 mm Hg (n=6). After phentolamine, with both anaesthetics, there was no response to doses of noradrenaline up to 640 ng or to ergometrine from 40 to 2000 ng. The response to vasopressin was only slightly reduced.
In-vitro Studies. Intrinsic activity.
Log molar concentration response relationships for noradrenaline, ergometrine and tyramine on the rabbit aorta and portal vein preparations are shown in figure 1. Three points are illustrated by this figure. Firstly, although the portal vein preparation is less sensitive to noradrenaline and more sensitive to tyramine than the aorta, both preparations are equally sensitive to ergometrine. Secondly, on the venous preparation, ergometrine is almost equipotent with noradrenaline. Thirdly, the nwgimiifp response to ergometrine on the vein and to tyramine on both preparations is considerably less man the i response to noradrenaline.
Effects of reserpinization and exposure to cocaine. Similar results were obtained using both the reserpinized portal vein and the vein exposed to a noradrenaline uptake blocking concentration of cocaine (45 min exposure to lXl0~5M cocaine; Kelly, 1971) . The responses to noradrenaline, ergometrine and tyramine obtained using these tissues are shown in figure 2 . The control responses to the three agonists obtained in the two series of experiments have been bulked since there was no significant difference between them. However, it should be pointed out that the control responses in the cocaine experiments were obtained on the same preparation as the test responses whereas separate, but concurrently examined, preparations were used for the reserpinized tissue controls.
The reserpinized vein and the cocaine-treated vein are more sensitive to noradrenaline, less sensitive to tyramine, and have the same sensitivity to ergometrine as untreated vein.
Interactions with noradrenaline.
Low concentrations of ergometrine which had no demonstrable agonist action had no effect on the responses of either the aorta or the portal vein to noradrenaline. Higher concentrations of ergometrine gave responses, together with noradrenaline, somewhat less than might be expected if simple summation of effects had occurred. Indeed if the higher concentrations of ergometrine were added to a tissue contracted to noradrenaline, a concentration-dependent inhibition of contraction was seen. This is shown in table II together with the effects of these concentrations of ergometrine on the portal vein preparation maximally contracted to potassium ion. On this preparation it was found that the contractions to potassium were not modified by a concentration of phentolamine which significantly reduced the response to noradrenaline. Although ergometrine did suppress the potassium mgirimnm this was significantly less than the suppression of the noradrenaline 
Interactions with phentolamine.
The effects of increasing concentrations of phentolamine on the cumulative concentration response curve to ergometrine obtained on the rabbit portal vein are shown in figure 3 . The curve is progressively shifted to the right although there does appear to be some diminution of the maximum response. In a series of seven experiments the mean pA, value for phentolamine against ergometrine was 8.3 ±0.14. The mean pA,-pA 10 value was 0.96±0.l5. Thus there is some indication that the antagonism of ergometrine by phentolamine may be competitive, although the diminution of the ergometrine minrimiim response demonstrates that not all of the criteria for competitive antagonism are fulfilled. Barrett (1971) showed that the cardiovascular effects of some drugs varied with the anaesthetic used for the procedure. It was concluded that this was the result of the varied effects of the anaesthetics upon autonomic function.
Urethane is an anaesthetic which increases autonomic function and has been shown to release adrenaline from the adrenal medulla (Spriggs, 1965) . Pentobarbitone, on the other hand, is believed to depress autonomic function and depress release of adrenaline from the adrenal medulla (Barrett, 1971; Spriggs, 1965) .
In our experiments propranolol was shown to depress heart rate and increase arterial pressure in the rat anaesthetized with urethane, but not in the rat anaesthetized with pentobarbitone, thus confirming the findings of Barrett (1971) . We have also shown that the rat anaesthetized with urethane is more sensitive to the pressor effects of ergometrine, whereas the sensitivity to noradrenaline and vasopressin is similar to that in pentobarbitone-anaesthetized rats.
Increased sensitivity to ergometrine in conditions of high autonomic tone could account for the clinical observations of Baillie (1963b) , who reported that young hypertensive patients were particularly sensitive to the pressor effects of ergometrine.
The pressor effects of ergometrine were not reduced by propranolol, but were completely abolished by phentolamine in a dose which abolished the action of noradrenaline, but not that of vasopressin. Similar results were obtained with both anaesthetics. Thus it seems that the pressor actions of ergometrine are mediated via the alphaadrenoceptor.
The rabbit aorta preparation and the portal vein preparation differ in that the former has a very sparse adrenergic innervation (Shibata et al., 1971) . Kelly (1971) found that the potentiation of noradrenaline by an uptake blocking concentration of cocaine was much less on the aorta than on the portal vein. Thus, when noradrenaline is added extrinsically to the aorta, most of the drug acts directly on the alpha-adrenoceptors, whilst on the portal vein, a more densely innervated tissue, more noradrenaline is taken up into the nerve terminal and less acts directly on the receptors. Similarly tyramine is less active on the aorta because there is less intrinsic noradrenaline in the tissue for it to release. The fact that ergometrine has a similar potency on both preparations suggests, firstly, that it is not exclusively taken up into noradrenergic nerves, and secondly, that it does not act exclusively by releasing noradrenalinc. There was no reduction in sensitivity to ergometrine in tissues which had been depleted of noradrenaline by reserpine or in tissues where uptake into noradrenergic neurone had been inhibited by cocaine.
One further point about the results obtained with reserpinized preparations requires comment. The noradrenaline sensitivity of the reserpinized rabbit portal vein was increased, but the sensitivity to ergometrine was not increased. It has been demonstrated that the supersensitivity which occurs in reserpinized tissues involves a number of agonists which suggests that it is non-specific in nature (Trendelenburg and Weiner, 1962) . However, Hudgins and Fleming (1966) have demonstrated that reserpinization may lead to a partial non-specific supersensitivity on some preparations. They demonstrated, on the reserpinized rabbit aorta, that sensitivity to noradrenaline, acetyieholine and potassium ion was increased, but sensitivity to hjstamine, 5-hydroxytryptamine and angiotensin was unchanged. Nevertheless our observation that supersensitivity occurs to noradrenaline, which acts on alpha-receptors, and not to ergometrine, which also appears to act on alpha-receptors, is interesting and requires further study.
It has been suggested that some ergot alkaloids might inhibit uptake of noradrenaline (Pacha and Salzmann, 1970) . Our experiments with noradrenaline and ergometrine in vitro produced no evidence that ergometrine might prevent re-uptake of noradrenaline. Potentiation of noradrenaline was not seen with any concentration of ergometrine. Very high concentrations of ergometrine had some antagonist action and since this action was more effective against noradrenaline than potassium, ergometrine may have some alpha-blocking actions in addition to non-specific depressant actions at these concentrations. This would explain the maximum response to ergometrine being lower than that produced by noradrenaline and the slight diminution of ma-gimiiTn response to ergometrine seen in the phentolamine experiments.
The in-vivo experiments suggested that the pressor response to ergometrine was mediated via the alpha-adrenoceptor. The pA, value for phentolamine against ergometrine on the portal vein in vitro was 8.3 ±0.14. This indicates that ergometrine is a fairly specific alpha agonist since the pA a for phentolamine against noradrenaline on this tissue was found to be 8.15 ± 0.07 (Kelly, 1971) . In summary our results have shown that the vasoconstrictor effects of ergometrine are mediated by a direct action on alpha-adrenoceptors. In vivo, preparations with high autonomic function appear to be particularly sensitive to ergometrine. However the experiments in vitro have failed to determine the mechanism for this action, although they have shown that uptake blocking actions, or release of noradrenaline from nerve terminals are unlikely to be important factors.
Although direct comparisons between the animal and human situation are unwise, our results support the views of Brooke and Robinson (1970) and Johnstone (1972) that ergometrine is a more potent pressor agent than is commonly thought and that there are particular dangers to its use in patients with high autonomic tone.
